Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization
Open Access
- 1 April 2001
- journal article
- Published by Wiley in The FASEB Journal
- Vol. 15 (6) , 1021-1027
- https://doi.org/10.1096/fj.00-0393com
Abstract
High levels of the plasminogen activators, but also their inhibitor, plasminogen activator inhibitor 1 (PAI-1), have been documented in neovascularization of severe ocular pathologies such as diabetic retinopathy or age-related macular degeneration (AMD). AMD is the primary cause of irreversible photoreceptors loss, and current therapies are limited. PAI-1 has recently been shown to be essential for tumoral angiogenesis. We report here that deficient PAI-1 expression in mice prevented the development of subretinal choroidal angiogenesis induced by laser photocoagulation. When systemic and local PAI-1 expression was achieved by intravenous injection of a replication-defective adenoviral vector expressing human PAI-1 cDNA, the wild-type pattern of choroidal angiogenesis was restored. These observations demonstrate the proangiogenic activity of PAI-1 not only in tumoral models, but also in choroidal experimental neovascularization sharing similarities with human AMD. They identify therefore PAI-1 as a potential target for therapeutic ocular anti-angiogenic strategies.Keywords
This publication has 24 references indexed in Scilit:
- Polarized Vascular Endothelial Growth Factor Secretion by Human Retinal Pigment Epithelium and Localization of Vascular Endothelial Growth Factor Receptors on the Inner Choriocapillaris: Evidence for a Trophic Paracrine RelationPublished by Elsevier ,1999
- Fas ligand (CD95 ligand) controls angiogenesis beneath the retinaNature Medicine, 1999
- The urokinase-type plasminogen activator system in cancer metastasis: A reviewInternational Journal of Cancer, 1997
- Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factorAmerican Journal of Ophthalmology, 1996
- Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases.Proceedings of the National Academy of Sciences, 1996
- Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor–type integrins inhibits retinal neovascularizationNature Medicine, 1996
- Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization.Proceedings of the National Academy of Sciences, 1995
- Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal DisordersNew England Journal of Medicine, 1994
- Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophyNature Genetics, 1994
- Requirement of Vascular Integrin α v β 3 for AngiogenesisScience, 1994